Chief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)

In this article:

John Boniface, Chief Scientific Officer of Sera Prognostics Inc (NASDAQ:SERA), has sold 21,438 shares of the company on March 26, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $9.55 per share, resulting in a total value of $204,682.90.

Sera Prognostics Inc is a company focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients. The company's tests are designed to predict the risk of preterm birth, preeclampsia, and other pregnancy complications, enabling more informed clinical decisions.

Over the past year, the insider has sold a total of 55,930 shares of Sera Prognostics Inc and has not made any purchases of the stock. The recent sale by the insider is part of a trend observed over the past year, where there have been 18 insider sells and no insider buys.

On the date of the insider's recent sale, shares of Sera Prognostics Inc were trading at $9.55, giving the company a market capitalization of $308.044 million.

Chief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)
Chief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)

The insider transaction history and the absence of insider purchases over the past year may be of interest to shareholders and potential investors as they evaluate the company's stock performance and insider confidence.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.

Advertisement